Top Health Tech Companies in Melbourne (50)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Strong Revenue Growth: Public disclosures indicate revenue surpassed $1B in 2023 and remained above that level in 2024–2025, with 2024 noted at roughly $1.1B. These signals point to ongoing top‑line expansion.
Product Line Growth: Recent launches and releases such as IntelliCare and the 2026.1 updates for IRIS, IRIS for Health, and Health Connect highlight an active roadmap. This cadence is presented as expanding the addressable market and creating new upsell paths.
Strong Market Position & Advantage: Industry recognition places the company as a Leader in the 2026 Gartner Magic Quadrant for Enterprise EHRs and the 2025–2026 IDC MarketScape for analytical databases, alongside multiple 2026 Best in KLAS #1 rankings. These placements signal competitive strength and buyer traction in core markets.
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Recent credit analysis highlights low-teen percentage growth in ARR and ACV since 2022, with projections for continued top-line expansion. Healthcare cybersecurity tailwinds and ongoing adoption on platforms like Azure support this momentum.
Healthy Cash Flow: An S&P upgrade in late 2025 cites improving cash flow with leverage expected to trend down through 2026. This points to stronger cash generation underpinning measured growth investments.
Product Line Growth: The October 2025 Verosint acquisition added AI-powered identity threat detection and risk signaling to the platform, broadening use cases. Continued Azure-aligned releases and clinical workflow enhancements indicate an expanding solution suite.
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
Nucleus Global is the largest specialist medical communications company in the world. Built on a reputation of scientific excellence and quality, we are a global leader in delivering world-class, innovative education and medical marketing services to the pharmaceutical and biotechnology industries.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
Doctify is a high-growth HealthTech company revolutionising the global healthcare market. Having expanded into 6 markets with an ambitious growth plan over the coming year. Doctify has developed a first-of-its-kind healthcare-specific patient feedback and review product allowing healthcare professionals to drive improvements in patient care on a daily basis. Our SaaS product allows healthcare providers to collect and digitize patient feedback and...
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New...
Bupa's Top Stability & Growth Strengths
Strong Revenue Growth: Group results show double‑digit revenue and underlying profit growth in 2024, with customers rising sharply. 2025 materials indicate continued revenue and profit increases alongside a larger customer base, with growth remaining solid even excluding first‑time consolidation effects.
Strong Market Position & Advantage: Independent market analysis places Bupa as the UK PMI leader within a concentrated 'big four', and official statistics show it as the largest fund in Australian private health insurance. Bupa Global is viewed as a tier‑one IPMI provider, and the insurer‑plus‑provider model strengthens competitive positioning across multiple regions.
Market Expansion: Company updates highlight ongoing expansion of clinics, dental centres, hospitals and digital health (Blua), with dozens of new sites opened in 2024 and further additions in 2025. Portfolio moves such as consolidating Niva Bupa in India and adding UK provision assets broaden reach into fast‑growing markets and channels.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists...
Do the work of your life to help the lives of others. As a leading health technology company, it is our purpose to improve people’s health and well-being through meaningful innovation. Our goal is to improve 2.5 billion lives per year by 2030. We also strive to be the best place to work for people who share our passion, by promoting...
Philips's Top Stability & Growth Strengths
Strong Market Position & Advantage: Philips is positioned as a leader across multiple health-technology categories, with cited top standings in interventional systems, PACS, monitoring, and a large installed base that supports ongoing competitiveness.
Profitability: Margins are described as improving, with adjusted EBITA expanding through 2025 and management targeting further margin improvement into the mid-teens by 2028.
Innovation-Driven Growth: Innovation capacity is reinforced through repeated recognition as a top global innovator, sustained R&D intensity, and an innovation roadmap expected to contribute meaningfully to growth and margin improvement.
The International SOS Group of Companies is in the business of saving lives, protecting global workforces from health and security threats. We deliver customised health, security risk management and wellbeing solutions to fuel our clients’ growth and productivity. In the event of extreme weather, an epidemic or a security incident, we provide an immediate response providing peace of mind. Our...
Nanochap is a fabless semiconductor company with its core R&D team based in Melbourne, Australia. We specialise in neural interface and biosensing SoCs. The company is committed to the R&D, design, packaging, testing, and commercialisation of ultra-high density neural interface chips, biosensing chips, and other medical device related chips.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly...
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed...
Smileyscope is a multi-award winning digital therapeutics company with proprietary technology that reframes medical procedures using choreographed virtual-reality (VR) experiences to help reduce patient pain and anxiety, and improve the overall patient experience. Our vision is to expand the frontiers of patient-centered care, improving the moments that matter most. Smileyscope VR is the first regulatory body approved VR product for...
At See-Mode, our mission is to unlock the hidden insights in medical imaging with AI, and empower clinicians to improve patient outcomes. Our AI-enhanced ultrasound reporting software automatically reads and assesses ultrasound images, producing accurate clinical reports.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to...
Moderna's Top Stability & Growth Strengths
Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.
Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.
Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.
